Methacholine reactivity predicts changes in lung function over time in smokers with early chronic obstructive pulmonary disease. The Lung Health Study Research Group - PubMed (original) (raw)
Clinical Trial
. 1996 Jun;153(6 Pt 1):1802-11.
doi: 10.1164/ajrccm.153.6.8665038.
Affiliations
- PMID: 8665038
- DOI: 10.1164/ajrccm.153.6.8665038
Clinical Trial
Methacholine reactivity predicts changes in lung function over time in smokers with early chronic obstructive pulmonary disease. The Lung Health Study Research Group
D P Tashkin et al. Am J Respir Crit Care Med. 1996 Jun.
Abstract
As part of a clinical trial of early intervention in chronic obstructive pulmonary disease (COPD) (the Lung Health Study), 5,733 smokers with mild to moderate airflow obstruction underwent methacholine challenge tests at baseline. All participants were randomized to receive either usual care (no intervention) or special intervention, consisting of intensive smoking cessation counseling and the prescription of a metered-dose inhaler containing either ipratropium bromide or placebo (two inhalations three times daily). For this report, we analyzed the relationship between baseline methacholine reactivity and subsequent change in lung function. Methacholine reactivity was expressed as a logarithmic function of the two-point slope of percent decline in FEV1 over the concentration of methacholine (LMCR). Using a random effects linear model, LMCR was found to be a strong predictor of change in FEV1% predicted, after controlling for baseline lung function, age, sex, baseline smoking history, and changes in smoking status. Significant interactions were found between reactivity and smoking behavior. In the first year, participants who quit smoking showed improvement in FEV1, whereas continuing smokers showed worsening, and between Years 1 and 5, lung function declined to a greater extent in continuing smokers than in sustained quitters. For both time periods, these quitter/smoker differences increased as a function of airway reactivity. These findings indicate that methacholine reactivity is an important predictor of progression of airway obstruction in continuing smokers with early COPD, independent of the baseline level of obstruct.
Similar articles
- The lung health study: airway responsiveness to inhaled methacholine in smokers with mild to moderate airflow limitation. The Lung Health Study Research Group.
Tashkin DP, Altose MD, Bleecker ER, Connett JE, Kanner RE, Lee WW, Wise R. Tashkin DP, et al. Am Rev Respir Dis. 1992 Feb;145(2 Pt 1):301-10. doi: 10.1164/ajrccm/145.2_Pt_1.301. Am Rev Respir Dis. 1992. PMID: 1736734 Clinical Trial. - Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study.
Scanlon PD, Connett JE, Waller LA, Altose MD, Bailey WC, Buist AS, Tashkin DP; Lung Health Study Research Group. Scanlon PD, et al. Am J Respir Crit Care Med. 2000 Feb;161(2 Pt 1):381-90. doi: 10.1164/ajrccm.161.2.9901044. Am J Respir Crit Care Med. 2000. PMID: 10673175 Clinical Trial. - Risk factors for accelerated decline among patients with chronic obstructive pulmonary disease.
Kerstjens HA, Brand PL, Postma DS. Kerstjens HA, et al. Am J Respir Crit Care Med. 1996 Dec;154(6 Pt 2):S266-72. doi: 10.1164/ajrccm/154.6_Pt_2.S266. Am J Respir Crit Care Med. 1996. PMID: 8970399 Review. - The impact of smoking cessation on respiratory symptoms, lung function, airway hyperresponsiveness and inflammation.
Willemse BW, Postma DS, Timens W, ten Hacken NH. Willemse BW, et al. Eur Respir J. 2004 Mar;23(3):464-76. doi: 10.1183/09031936.04.00012704. Eur Respir J. 2004. PMID: 15065840 Review.
Cited by
- Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023 Guidelines Reviewed.
Sharma M, Joshi S, Banjade P, Ghamande SA, Surani S. Sharma M, et al. Open Respir Med J. 2024 Jan 10;18:e18743064279064. doi: 10.2174/0118743064279064231227070344. eCollection 2024. Open Respir Med J. 2024. PMID: 38660684 Free PMC article. Review. - Bronchodilator Responsiveness in Tobacco-Exposed People With or Without COPD.
Fortis S, Quibrera PM, Comellas AP, Bhatt SP, Tashkin DP, Hoffman EA, Criner GJ, Han MK, Barr RG, Arjomandi M, Dransfield MB, Peters SP, Dolezal BA, Kim V, Putcha N, Rennard SI, Paine R 3rd, Kanner RE, Curtis JL, Bowler RP, Martinez FJ, Hansel NN, Krishnan JA, Woodruff PG, Barjaktarevic IZ, Couper D, Anderson WH, Cooper CB; Subpopulations and Intermediate Outcome Measures in COPD Study Investigators. Fortis S, et al. Chest. 2023 Mar;163(3):502-514. doi: 10.1016/j.chest.2022.11.009. Epub 2022 Nov 15. Chest. 2023. PMID: 36395858 Free PMC article. - Phenotypic spectrum of _FGF10_-related disorders: a systematic review.
Bzdega K, Karolak JA. Bzdega K, et al. PeerJ. 2022 Sep 14;10:e14003. doi: 10.7717/peerj.14003. eCollection 2022. PeerJ. 2022. PMID: 36124135 Free PMC article. - Genetic Determinants in Airways Obstructive Diseases: The Case of Asthma Chronic Obstructive Pulmonary Disease Overlap.
Saferali A, Hersh CP. Saferali A, et al. Immunol Allergy Clin North Am. 2022 Aug;42(3):559-573. doi: 10.1016/j.iac.2022.03.003. Epub 2022 Jun 30. Immunol Allergy Clin North Am. 2022. PMID: 35965045 Free PMC article. Review. - Direct Visualization and Quantitative Imaging of Small Airway Anatomy In Vivo Using Deep Learning Assisted Diffractive OCT.
Yuan W, Thiboutot J, Park HC, Li A, Loube J, Mitzner W, Yarmus L, Brown RH, Li X. Yuan W, et al. IEEE Trans Biomed Eng. 2022 Jul 4;PP:10.1109/TBME.2022.3188173. doi: 10.1109/TBME.2022.3188173. Online ahead of print. IEEE Trans Biomed Eng. 2022. PMID: 35786546 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials